Results 51 to 60 of about 6,517,332 (327)

Australian Homelessness Monitor 2018 [PDF]

open access: yes, 2018
Launch Housing has commissioned the Australian Homelessness Monitor 2018 (the Monitor), for this first-of-its-kind authoritative insight into the current state of homelessness in Australia.
Parsell, Cameron   +9 more
core   +1 more source

Planckpre-launch status: Design and description of the Low Frequency Instrument [PDF]

open access: yesAstronomy and Astrophysics, 2010
In this paper we present the Low Frequency Instrument (LFI), designed and developed as part of the Planck space mission, the ESA program dedicated to precision imaging of the cosmic microwave background (CMB). Planck-LFI will observe the full sky in intensity and polarisation in three frequency bands centred at 30, 44 and 70 GHz, while higher ...
M Bersanelli   +112 more
openaire   +16 more sources

HIRDLS Pre-Launch Presentations

open access: yes, 2000
Previously curated at: http://cedadocs.ceda.ac.uk/1137/ Event type: conference. The publish date on this item was its original completed date. This item was not refereed before the publication Main files in this record: HIRDLS_Pre-Launch_Presentation_1.pdf HIRDLS_Pre-Launch_Presentation_2.pdf HIRDLS_Pre-Launch_Presentation_3.pdf HIRDLS_Pre ...
Gille, John, Barnett, John
openaire   +2 more sources

Airship-assisted space launch. [PDF]

open access: yes, 2004
Introduction Being lighter-than-air, airships do not seem to be an obvious platform choice for dropping of heavy objects. We have challenged the idea and this paper presents the summary of a speculative concept which utilises airships as a reusable ...
Guenov, Marin D., Peyron, Vincent
core  

Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades

open access: yesBMC Health Services Research, 2022
Background The timing of the launch of a new drug is an important factor that determines access for patients. We evaluated patient access to pharmaceuticals in 30 European markets over the past two decades.
Melanie Büssgen, Tom Stargardt
doaj   +1 more source

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook   +6 more
wiley   +1 more source

Performance comparison of reusable launch vehicles [PDF]

open access: yes, 2005
Paper presented at Dynamics and Control of Systems and Structures in Space (DCSSS), 5th conference, Kings College, Cambridge, July 2002A parameterised generic launch vehicle design is subjected to performance evaluation using the ORBITER model which is ...
Ayre, Mark, Bowling, Tom
core  

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) is assessed by cell counting and cytomorphology from cerebrospinal fluid (CSF) and is used for treatment stratification worldwide. The ratio of “CNS2” patients in clinical trials ranges from 3% to 40%, with unclear prognostic significance ...
Laura Almási   +14 more
wiley   +1 more source

Dabigatran – an exemplar case history demonstrating the need for comprehensive models to optimise the use of new drugs

open access: yesFrontiers in Pharmacology, 2014
Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/ or budget concerns.
Brian eGodman   +37 more
doaj   +1 more source

The Role of Hematopoietic Cell Transplantation in Ataxia‐Telangiectasia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Ataxia‐telangiectasia (A‐T) is a DNA repair disorder characterized by neurodegeneration, immunodeficiency, and cancer predisposition. Hematopoietic cell transplantation (HCT) is an established therapy in related disorders such as Fanconi anemia (FA) and Nijmegen breakage syndrome (NBS), but its role in A‐T is unclear.
Laila Alkhouli   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy